Semaglutide 2 mg/1.5 ml (1.34 mg/ml), prefilled pen-injector for subcutaneous injection solution

DRUG2 trials

Sponsors

Geisinger Clinic, Zagazig University

Conditions

CKDDiabetic Kidney DiseaseObese DiabeticsObese Non DiabeticObesitySevere ObesityType 2 Diabetes Mellitus in Obese

Phase 3

Effect of Subcutaneous Semaglutide on Kidney Transplant Candidacy

TerminatedNCT04741074

Geisinger ClinicCKD, Diabetic Kidney Disease, Obesity +2

Start: 2021-07-23End: 2023-01-31Updated: 2024-02-09

Comparative Study of Different Weekly GLP-1 Receptor Agonists Among Diabetic and Non-Diabetic Patients: Clinical Trial

CompletedNCT07820111

Zagazig UniversityObese Diabetics, Obese Non Diabetic

Start: 2025-10-18End: 2026-03-17Updated: 2026-09-15